Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced that it received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) supporting its plans for an adaptive Phase 2 field study of TNX-4800, a long-acting anti-OspA monoclonal antibody candidate designed to prevent Lyme disease. This regulatory feedback marks a significant step forward in the development of a potential new preventive option for a tick-borne illness that affects hundreds of thousands of Americans each year.
According to the company, the planned randomized, placebo-controlled study is expected to enroll approximately 3,300 adults over two Lyme disease seasons. The trial will evaluate the prevention of Lyme disease through six months after dosing, with manufacturing of the investigational product on track for delivery to study sites in the first quarter of 2027. TNX-4800 is being developed as a seasonal immunopreventative administered as two subcutaneous injections three months apart, with the potential to provide protection throughout the U.S. Lyme disease season.
The FDA's feedback is crucial as it aligns with the company's study design and supports the path forward. This development is important because Lyme disease is the most common vector-borne disease in the United States, with the CDC estimating around 476,000 cases annually. Current prevention methods primarily rely on tick avoidance and early antibiotic treatment, but a preventive monoclonal antibody could offer a new layer of protection for individuals in high-risk areas.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra.
Beyond its CNS focus, Tonix is advancing a pipeline of immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The announcement is particularly relevant to public health, as Lyme disease can cause severe symptoms if left untreated, including arthritis, neurological issues, and cardiac complications. A seasonal preventive like TNX-4800 could reduce the burden of disease and the associated healthcare costs. For investors, this news signals progress in Tonix's pipeline and potential market expansion beyond CNS treatments.
For more information on Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/pe0eP.
